Lilly Launches Full Range of Zepbound Doses via LillyDirect
TL;DR Summary
Eli Lilly announced that all approved doses of Zepbound (tirzepatide) for obesity treatment will be available in single-dose vials for $499/month or less through LillyDirect's Self Pay Pharmacy Solutions, making the medication more accessible regardless of insurance, with shipments starting in early August.
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
14 min
vs 15 min read
Condensed
99%
2,939 → 43 words
Want the full story? Read the original article
Read on Eli Lilly and Company